Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CYTC - How High Can It Go! -- Ignore unavailable to you. Want to Upgrade?

To: Cisco who wrote (60)	11/21/1997 2:04:00 PM
From: Ted Downs	Read Replies (1) \| Respond to of 185

Cisco, I speed read a lot of news, info etc. and this is what caught my eye. <<ThinPrep Method for Cervical-Vaginal Specimens in a High-Risk Population'' concluded, ''These preliminary findings indicate several advantages for the ThinPrep method in a high-risk population:identification of more pre-malignant lesions, reduction in the number of inconclusive diagnoses and improved specimen adequacy.''>> <<In another study of over 50,000 patients in Australia, Dr. Colin Laverty found that more cervical abnormalities were identified on ThinPrep slides than on conventional Pap smears. The ThinPrep Pap Test also resulted in an increase in biopsy confirmed high-grade lesions and improved specimen adequacy. >> I went back and saw the info regarding sampling errors after you mentioned it was the same conference. I still don't think it is meaningful. However, I will watch from the sidelines since I sold this AM in order to raise cash for an IPO I received today. I will continue bookmarking this co. and watch with interest. Good Luck. Ted